Earlier today, the UCI advised German rider Patrik Sinkewitz that he is provisionally suspended. The decision to provisionally suspend Mr Sinkewitz was made in response to a report from the WADA accredited laboratory in Lausanne indicating an Adverse Analytical Finding of Recombinant Human Growth Hormone in a blood sample collected from him at an in-competition test carried out by Antidoping Switzerland, authorized by the UCI, at the GP di Lugano on 27 February 2011.
This is the first suspension delivered in cycling on the basis of a test for the detection of the growth hormone and one of the first cases in all sports combined. This adverse analytical finding is therefore a new and important step in cyclingâ€™s fight against doping.
The provisional suspension remains in force until a hearing panel convened by the German Cycling Federation determines whether Mr Sinkewitz has committed an anti-doping rule violation under Article 21 of the UCI Anti-Doping Rules.
Mr Sinkewitz has the right to request and attend the analyses of his B sample.
Under the World Anti-Doping Code and the UCI Anti-Doping Rules, the UCI is unable to provide any additional information at this time.
UCI Press Services